Celgene's Solid Quarter Enhanced By Strong Interim Data For Revlimid
This article was originally published in The Pink Sheet Daily
Executive Summary
A pivotal trial to expand labeling to first-line multiple myeloma therapy was stopped after the first interim data readout due to strong PFS data.